Hurun India Rich List 2026 edition · 1 director
- #243 Venkateswarlu Jasti & family ₹15,000 Cr
Market Cap
₹8,196 Cr
SUVEN · NSE
Share Price
₹290.05
-4.45% today
Revenue
₹7.11 Cr
FY 2025-26 · +6.8% YoY
EBITDA
−₹284 Cr
Margin -3,999.4%
Net Profit
−₹286 Cr
FY 2025-26 · -72.5% YoY
Debt / Equity
0.02
Interest cover -0.1x
Authorised capital
₹50 Cr
Registered with MCA
Paid-up capital
₹26.4 Cr
Issued & subscribed
About Suven Life Sciences Limited
Data last updated:
Suven Life Sciences Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Jasti Property And Equity Holdings Private Limited. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 09 March 1989 and has been in existence for over 37 years.
Its director Venkateswarlu Jasti and family are #243 on the Hurun India Rich List 2026.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24110TG1989PLC009713. Its GSTIN is 36AADCS4044C1ZQ (Telangana). The company holds 2 GST registrations, all of them active. Its shares are listed on BSE: 530239 and NSE: SUVEN.
The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹26.4 Cr. It was formerly known as Suven Synthesis Ltd and Suven Pharmaceuticals Pvt Ltd. It is led by directors including Venkateswarlu Jasti (Managing Director) and Sudharani Jasti (Whole-Time Director).
Its last annual general meeting (AGM) was held on 22 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Door No. 8 – 2 – 334 6th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹7.11 Cr, a growth of 6.8% compared to the previous year. For the same year it recorded a net loss of ₹285.89 Cr and EBITDA of -₹284.36 Cr. The net worth stands at ₹591.39 Cr (up 437.7% YoY). Total assets are valued at ₹610.01 Cr (up 446.1% YoY).
The company has about 137 employees on its provident fund (EPFO) records.
The company is associated with 3 brands: Suven Nishtaa, Suven Life Sciences and Suven Pharma. As per MCA filings, the company has satisfied charges of ₹239.04 Cr on record. Court records list 13 cases involving the company, including 7 filed by the company and 4 filed against it; 1 case is pending. The company has 19 deals on record (15 market trades, 2 funding rounds, 1 qip), with disclosed funding of ₹295.28 Cr; the latest was in January 2024. Its 10 peer companies in the Pharma industry (Contract Research) are compared by revenue, 5 larger and 5 smaller; the largest is Vivancemed India Private Limited with revenue of ₹18.19 Cr. The company has 7 MSME Form 1 returns on record between 2019 and 2021, listing 354 overdue payments to 38 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website suven.com.
Company Details of Suven Life Sciences Limited
CIN L24110TG1989PLC009713
Registration Number 009713
Incorporation Date 09 March 1989
ROC Hyderabad
Listing Status Listed (BSE: 530239, NSE: SUVEN)
Company Status Active
Date of Last AGM 22 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Jasti Property And Equity Holdings Private Limited
Compliance Status Active Compliant
Name History of Suven Life Sciences Limited
Suven Life Sciences has undergone 2 name changes throughout its history. The company was previously known as Suven Synthesis Ltd, and Suven Pharmaceuticals Pvt Ltd. The current legal name is Suven Life Sciences Limited.
| Company Name | Status |
|---|---|
| Suven Life Sciences Limited | Current |
| Suven Synthesis Ltd | Previous |
| Suven Pharmaceuticals Pvt Ltd | Previous |
CIN History of Suven Life Sciences Limited
Suven Life Sciences has one previous CIN (Corporate Identification Number): L24110AP1989PLC009713. The current CIN is L24110TG1989PLC009713, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1989PLC009713 | Current |
| L24110AP1989PLC009713 | Previous |
Key People
Venkateswarlu Jasti Managing Director Sudharani Jasti Whole-Time Director Santanu Mukherjee Director Recognitions & Rankings of Suven Life Sciences
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressDoor No. 8 – 2 – 334 6th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034
- IndustryPharma, Pharma Contract R&D
Comprehensive company report
Suven Life Sciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Suven Life Sciences Limited
Suven Life Sciences operates multiple associated brands including Suven Nishtaa, Suven Life Sciences, and Suven Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Online drug store | suvennishtaa.com | |
| CDMO services and CNS drug discovery pipeline are offered. | suven.com | |
| Contract manufacturing and development of APIs and formulations are provided. | suvenpharm.com |
Business Activity of Suven Life Sciences Limited
The main business activity of Suven Life Sciences is professional, scientific and technical. In detail, this covers scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Suven Life Sciences Limited FY 2025-26 filings available
Suven Life Sciences Limited reported revenue of ₹7.11 Cr (up 6.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹7.11 Cr
+6.8% YoY
EBITDA
−₹284 Cr
-71.7% YoY
Profit After Tax
−₹286 Cr
-72.5% YoY
Net Worth
₹591 Cr
+437.7% YoY
Total Assets
₹610 Cr
+446.1% YoY
Total Debt
₹16.69 Cr
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 7.11 | 6.66 | 11.69 | 13.54 | 11.84 | 13.48 | 14.41 |
| Revenue growth | +6.8% | -43.0% | -13.7% | +14.4% | -12.2% | -6.5% | - |
| EBITDA | (284) | (166) | (128) | (126) | (122) | (79.95) | (116) |
| EBITDA margin | -3999.4% | -2487.2% | -1093.8% | -928.7% | -1032.5% | -593.1% | -803.0% |
| Profit before tax | (276) | (161) | (106) | (118) | (122) | (77.49) | (106) |
| Net profit | (286) | (166) | (117) | (126) | (126) | (72.23) | (94.71) |
| Net profit margin | -4021.0% | -2488.3% | -1001.6% | -930.9% | -1064.0% | -535.8% | -657.3% |
| EPS (₹) | (10.48) | (7.37) | (4.82) | (5.42) | (8.39) | (5.67) | (7.40) |
| Balance sheet | |||||||
| Total assets | 610 | 112 | 272 | 379 | 101 | 115 | 152 |
| Net worth | 591 | 110 | 270 | 375 | 96.15 | 108 | 143 |
| Total debt | 16.69 | 0.00 | 0.71 | 1.61 | 3.21 | 4.76 | 6.01 |
| Cash & bank | 337 | 37.73 | 164 | 184 | 5.52 | 46.65 | 15.09 |
| Net working capital | 352 | 29.71 | 168 | 195 | 14.75 | 88.73 | 41.43 |
| Cash flow | |||||||
| Cash from operations | (300) | (155) | (115) | (116) | (128) | (96.02) | (135) |
| Cash from investing | (462) | 155 | 94.44 | (248) | (22.23) | 55.84 | 146 |
| Cash from financing | 757 | (0.76) | (1.05) | 396 | 146 | 34.86 | 2.81 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.57 | 1.52 | 2.81 | 0.92 | 1.87 | 1.47 | 1.61 | 2.57 |
| Revenue growth (YoY) | +90.9% | +3.4% | +74.5% | -64.2% | +85.2% | - | - | - |
| Other income | 7.52 | 6.78 | 2.77 | 3.78 | 0.60 | 1.22 | 1.63 | 4.04 |
| EBITDA | (132) | (50.63) | (103) | (79.77) | (50.75) | (43.82) | (39.21) | (52.21) |
| EBITDA margin | -3711.5% | -3330.9% | -3677.9% | -8670.7% | -2713.9% | -2981.0% | -2435.4% | -2031.5% |
| Depreciation | 2.16 | 1.58 | 1.35 | 1.32 | 1.37 | 1.35 | 1.53 | 1.46 |
| Interest | 0.48 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Profit before tax | (128) | (45.59) | (102) | (77.31) | (51.52) | (43.95) | (39.12) | (49.65) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (128) | (45.59) | (102) | (77.31) | (51.52) | (43.95) | (39.12) | (49.65) |
| EPS (₹) | (4.84) | (2.02) | (4.55) | (3.48) | (2.36) | (2.02) | (1.79) | (2.27) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 7.11 | 6.66 | 11.69 | 13.54 | 11.84 | 13.48 | 14.41 |
| Revenue growth | +6.8% | -43.0% | -13.7% | +14.4% | -12.2% | -6.5% | - |
| EBITDA | (62.91) | (51.83) | (30.85) | (27.63) | (36.52) | (30.45) | (35.27) |
| EBITDA margin | -884.8% | -778.2% | -263.9% | -204.1% | -308.5% | -225.9% | -244.8% |
| Profit before tax | (54.87) | (47.07) | (9.00) | (20.12) | (36.23) | (27.96) | (25.94) |
| Net profit | (64.41) | (52.05) | (20.01) | (27.91) | (36.50) | (22.70) | (14.26) |
| Net profit margin | -905.9% | -781.5% | -171.2% | -206.1% | -308.3% | -168.4% | -99.0% |
| EPS (₹) | (2.08) | (2.16) | (0.37) | (0.92) | (2.49) | (1.78) | (1.08) |
| Balance sheet | |||||||
| Total assets | 1,522 | 801 | 847 | 857 | 481 | 408 | 396 |
| Net worth | 1,503 | 800 | 845 | 853 | 476 | 402 | 388 |
| Total debt | 16.69 | 0.00 | 0.71 | 1.61 | 3.21 | 4.76 | 6.01 |
| Cash & bank | 331 | 19.96 | 153 | 174 | 3.15 | 38.59 | 1.12 |
| Net working capital | 351 | 27.76 | 166 | 191 | 13.89 | 87.35 | 43.93 |
| Cash flow | |||||||
| Cash from operations | (67.71) | (48.60) | (20.56) | (22.92) | (36.62) | (36.68) | (45.15) |
| Cash from investing | (686) | 44.21 | (0.68) | (349) | (107) | 2.41 | 42.03 |
| Cash from financing | 757 | (0.76) | (1.05) | 396 | 146 | 34.86 | 3.81 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.57 | 1.52 | 2.81 | 0.92 | 1.87 | 1.47 | 1.61 | 2.57 |
| Revenue growth (YoY) | +90.9% | +3.4% | +74.5% | -64.2% | +85.2% | - | - | - |
| Other income | 7.52 | 6.78 | 2.77 | 3.78 | 0.59 | 1.19 | 1.57 | 4.03 |
| Total expenses | 24.58 | 17.72 | 17.70 | 18.83 | 15.87 | 16.38 | 14.91 | 16.21 |
| EBITDA | (21.01) | (16.20) | (14.89) | (17.91) | (14.00) | (14.91) | (13.30) | (13.64) |
| EBITDA margin | -588.5% | -1065.8% | -529.9% | -1946.7% | -748.7% | -1014.3% | -826.1% | -530.7% |
| Depreciation | 2.16 | 1.58 | 1.35 | 1.32 | 1.37 | 1.35 | 1.53 | 1.46 |
| Interest | 0.48 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Profit before tax | (16.13) | (11.16) | (13.47) | (15.45) | (14.78) | (15.07) | (13.27) | (11.09) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 20 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.57 | 1.52 | 2.81 | 0.92 | 1.87 | 1.47 | 1.61 | 2.57 |
| Revenue growth (YoY) | +90.9% | +3.4% | +74.5% | -64.2% | +85.2% | - | - | - |
| Other income | 7.52 | 6.78 | 2.77 | 3.78 | 0.60 | 1.22 | 1.63 | 4.04 |
| EBITDA | (132) | (50.63) | (103) | (79.77) | (50.75) | (43.82) | (39.21) | (52.21) |
| EBITDA margin | -3711.5% | -3330.9% | -3677.9% | -8670.7% | -2713.9% | -2981.0% | -2435.4% | -2031.5% |
| Depreciation | 2.16 | 1.58 | 1.35 | 1.32 | 1.37 | 1.35 | 1.53 | 1.46 |
| Interest | 0.48 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Profit before tax | (128) | (45.59) | (102) | (77.31) | (51.52) | (43.95) | (39.12) | (49.65) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (128) | (45.59) | (102) | (77.31) | (51.52) | (43.95) | (39.12) | (49.65) |
| EPS (₹) | (4.84) | (2.02) | (4.55) | (3.48) | (2.36) | (2.02) | (1.79) | (2.27) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 7.11 | 6.66 | 11.69 | 13.54 | 11.84 | 13.48 | 14.41 |
| Revenue growth | +6.8% | -43.0% | -13.7% | +14.4% | -12.2% | -6.5% | - |
| Other income | 13.93 | 10.90 | 28.59 | 14.45 | 5.32 | 7.75 | 14.04 |
| Total expenses | 291 | 172 | 140 | 139 | 134 | 93.43 | 130 |
| Employee cost | 24.15 | 20.82 | 18.99 | 18.62 | 21.02 | 18.53 | 17.41 |
| EBITDA | (284) | (166) | (128) | (126) | (122) | (79.95) | (116) |
| EBITDA margin | -3999.4% | -2487.2% | -1093.8% | -928.7% | -1032.5% | -593.1% | -803.0% |
| Depreciation | 5.61 | 5.82 | 6.50 | 6.54 | 4.39 | 4.35 | 4.17 |
| Interest | 0.31 | 0.17 | 0.30 | 0.41 | 0.67 | 0.94 | 0.55 |
| Profit before tax | (276) | (161) | (106) | (118) | (122) | (77.49) | (106) |
| Tax | 0.00 | 0.00 | (1.00) | 0.00 | 0.00 | (5.32) | (12.18) |
| Net profit | (286) | (166) | (117) | (126) | (126) | (72.23) | (94.71) |
| Net profit margin | -4021.0% | -2488.3% | -1001.6% | -930.9% | -1064.0% | -535.8% | -657.3% |
| EPS (₹) | (10.48) | (7.37) | (4.82) | (5.42) | (8.39) | (5.67) | (7.40) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 26.37 | 21.81 | 21.81 | 21.81 | 14.54 | 12.73 | 12.73 |
| Reserves & surplus | 410 | 88.18 | 248 | 354 | 81.61 | 58.36 | 131 |
| Shareholders' funds (net worth) | 591 | 110 | 270 | 375 | 96.15 | 108 | 143 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 16.69 | 0.00 | 0.71 | 1.61 | 3.21 | 4.76 | 6.01 |
| Total debt | 16.69 | 0.00 | 0.71 | 1.61 | 3.21 | 4.76 | 6.01 |
| Total liabilities | 610 | 112 | 272 | 379 | 101 | 115 | 152 |
| Assets | |||||||
| Gross block | 130 | 113 | 78.24 | 88.60 | 82.57 | 67.77 | 77.32 |
| Net block | 72.99 | 59.65 | 28.21 | 37.21 | 37.56 | 20.96 | 24.70 |
| Capital work in progress | 3.60 | 0.01 | 0.00 | 0.00 | 3.55 | 4.77 | 0.00 |
| Investments | 181 | 22.28 | 75.94 | 46.34 | 45.16 | 0.09 | 0.05 |
| Inventories | 0.10 | 0.24 | 0.71 | 0.00 | 0.02 | 0.14 | 0.00 |
| Sundry debtors | 1.51 | 1.34 | 1.29 | 0.81 | 1.30 | 1.76 | 2.27 |
| Cash & bank balances | 337 | 37.73 | 164 | 184 | 5.52 | 46.65 | 15.09 |
| Loans & advances | 26.99 | 13.89 | 14.76 | 20.16 | 14.59 | 54.04 | 48.58 |
| Total current assets | 366 | 53.20 | 181 | 205 | 21.43 | 103 | 65.94 |
| Total current liabilities | 14.20 | 23.49 | 12.81 | 10.11 | 6.68 | 13.86 | 24.51 |
| Net working capital | 352 | 29.71 | 168 | 195 | 14.75 | 88.73 | 41.43 |
| Total assets | 610 | 112 | 272 | 379 | 101 | 115 | 152 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 15.03 | 14.93 | 37.02 | 5.27 | 9.35 | 14.68 | 0.23 |
| Net cash from operating activities | (300) | (155) | (115) | (116) | (128) | (96.02) | (135) |
| Net cash from investing activities | (462) | 155 | 94.44 | (248) | (22.23) | 55.84 | 146 |
| Net cash from financing activities | 757 | (0.76) | (1.05) | 396 | 146 | 34.86 | 2.81 |
| Net change in cash | (5.23) | (1.12) | (22.09) | 31.75 | (4.07) | (5.33) | 14.45 |
| Closing cash | 337 | 37.73 | 164 | 184 | 5.52 | 46.65 | 15.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +6.8% | -43.0% | -13.7% | +14.4% | -12.2% | -6.5% | - |
| EBITDA growth | -71.7% | -29.6% | -1.7% | -2.9% | -52.9% | +30.9% | - |
| PBT growth | -71.9% | -51.5% | +10.3% | +3.1% | -57.4% | +27.2% | - |
| Net income growth | -72.5% | -41.5% | +7.1% | -0.1% | -74.4% | +23.7% | - |
| Revenue CAGR (3Y) | -19.3% | -17.5% | -4.6% | -2.1% | -65.4% | -72.2% | -70.2% |
| EBITDA CAGR (3Y) | +31.3% | +10.7% | +17.0% | +2.8% | +104.1% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -3886.8% | -2413.5% | -898.9% | -873.3% | -1030.3% | -535.4% | -653.8% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.02 | 0.00 | 0.00 | 0.01 | 0.04 | 0.04 | 0.02 |
| Long-term debt / equity | 0.02 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.02 |
| Interest cover | -0.11 | -0.10 | -0.22 | -0.31 | -0.53 | -1.12 | -0.46 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.06 | 0.07 | 0.14 | 0.16 | 0.16 | 0.19 | 0.25 |
| Inventory turnover | 41.82 | 14.02 | 32.93 | 1,354.00 | 148.00 | 192.57 | 0.00 |
| Debtors turnover | 4.99 | 5.06 | 11.13 | 12.83 | 7.74 | 6.69 | 5.87 |
| EPS (₹) | (10.48) | (7.37) | (4.82) | (5.42) | (8.39) | (5.67) | (7.40) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 16.53 | 5.04 | 12.38 | 17.21 | 6.61 | 5.58 | 11.26 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.57 | 1.52 | 2.81 | 0.92 | 1.87 | 1.47 | 1.61 | 2.57 |
| Revenue growth (YoY) | +90.9% | +3.4% | +74.5% | -64.2% | +85.2% | - | - | - |
| Other income | 7.52 | 6.78 | 2.77 | 3.78 | 0.59 | 1.19 | 1.57 | 4.03 |
| Total expenses | 24.58 | 17.72 | 17.70 | 18.83 | 15.87 | 16.38 | 14.91 | 16.21 |
| EBITDA | (21.01) | (16.20) | (14.89) | (17.91) | (14.00) | (14.91) | (13.30) | (13.64) |
| EBITDA margin | -588.5% | -1065.8% | -529.9% | -1946.7% | -748.7% | -1014.3% | -826.1% | -530.7% |
| Depreciation | 2.16 | 1.58 | 1.35 | 1.32 | 1.37 | 1.35 | 1.53 | 1.46 |
| Interest | 0.48 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Profit before tax | (16.13) | (11.16) | (13.47) | (15.45) | (14.78) | (15.07) | (13.27) | (11.09) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 7.11 | 6.66 | 11.69 | 13.54 | 11.84 | 13.48 | 14.41 |
| Revenue growth | +6.8% | -43.0% | -13.7% | +14.4% | -12.2% | -6.5% | - |
| Other income | 13.91 | 10.73 | 28.59 | 14.45 | 5.32 | 7.75 | 14.04 |
| Total expenses | 70.02 | 58.49 | 42.54 | 41.17 | 48.36 | 43.93 | 49.68 |
| Employee cost | 24.15 | 20.82 | 16.53 | 15.77 | 17.46 | 15.29 | 14.60 |
| EBITDA | (62.91) | (51.83) | (30.85) | (27.63) | (36.52) | (30.45) | (35.27) |
| EBITDA margin | -884.8% | -778.2% | -263.9% | -204.1% | -308.5% | -225.9% | -244.8% |
| Depreciation | 5.61 | 5.82 | 6.50 | 6.54 | 4.39 | 4.35 | 4.17 |
| Interest | 0.26 | 0.15 | 0.24 | 0.40 | 0.64 | 0.91 | 0.54 |
| Profit before tax | (54.87) | (47.07) | (9.00) | (20.12) | (36.23) | (27.96) | (25.94) |
| Tax | 0.00 | 0.00 | (1.00) | 0.00 | 0.00 | (5.32) | (12.18) |
| Net profit | (64.41) | (52.05) | (20.01) | (27.91) | (36.50) | (22.70) | (14.26) |
| Net profit margin | -905.9% | -781.5% | -171.2% | -206.1% | -308.3% | -168.4% | -99.0% |
| EPS (₹) | (2.08) | (2.16) | (0.37) | (0.92) | (2.49) | (1.78) | (1.08) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 26.37 | 21.81 | 21.81 | 21.81 | 14.54 | 12.73 | 12.73 |
| Reserves & surplus | 1,321 | 778 | 824 | 832 | 461 | 352 | 375 |
| Shareholders' funds (net worth) | 1,503 | 800 | 845 | 853 | 476 | 402 | 388 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 16.69 | 0.00 | 0.71 | 1.61 | 3.21 | 4.76 | 6.01 |
| Total debt | 16.69 | 0.00 | 0.71 | 1.61 | 3.21 | 4.76 | 6.01 |
| Total liabilities | 1,522 | 801 | 847 | 857 | 481 | 408 | 396 |
| Assets | |||||||
| Gross block | 130 | 113 | 78.32 | 88.60 | 83.40 | 67.77 | 77.32 |
| Net block | 72.99 | 59.65 | 28.21 | 37.21 | 37.57 | 20.96 | 24.70 |
| Capital work in progress | 3.60 | 0.01 | 0.00 | 0.00 | 3.55 | 4.77 | 0.00 |
| Investments | 1,094 | 714 | 653 | 528 | 426 | 295 | 242 |
| Inventories | 0.10 | 0.24 | 0.71 | 0.00 | 0.02 | 0.14 | 0.00 |
| Sundry debtors | 1.51 | 1.34 | 1.29 | 0.81 | 1.30 | 1.76 | 2.27 |
| Cash & bank balances | 331 | 19.96 | 153 | 174 | 3.15 | 38.59 | 1.12 |
| Loans & advances | 26.99 | 13.89 | 14.76 | 20.16 | 14.59 | 54.04 | 48.55 |
| Total current assets | 360 | 35.43 | 170 | 195 | 19.06 | 94.53 | 51.94 |
| Total current liabilities | 9.08 | 7.67 | 4.05 | 3.51 | 5.17 | 7.18 | 8.01 |
| Net working capital | 351 | 27.76 | 166 | 191 | 13.89 | 87.35 | 43.93 |
| Total assets | 1,522 | 801 | 847 | 857 | 481 | 408 | 396 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.46 | 4.40 | 26.70 | 2.90 | 1.29 | 0.71 | 0.01 |
| Net cash from operating activities | (67.71) | (48.60) | (20.56) | (22.92) | (36.62) | (36.68) | (45.15) |
| Net cash from investing activities | (686) | 44.21 | (0.68) | (349) | (107) | 2.41 | 42.03 |
| Net cash from financing activities | 757 | (0.76) | (1.05) | 396 | 146 | 34.86 | 3.81 |
| Net change in cash | 3.34 | (5.15) | (22.30) | 23.79 | 1.61 | 0.58 | 0.69 |
| Closing cash | 331 | 19.96 | 153 | 174 | 3.15 | 38.59 | 1.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +6.8% | -43.0% | -13.7% | +14.4% | -12.2% | -6.5% | - |
| EBITDA growth | -21.4% | -68.0% | -11.7% | +24.3% | -19.9% | +13.7% | - |
| PBT growth | -16.6% | -423.0% | +55.3% | +44.5% | -29.6% | -7.8% | - |
| Net income growth | -23.8% | -160.1% | +28.3% | +23.5% | -60.8% | -59.2% | - |
| Revenue CAGR (3Y) | -19.3% | -17.5% | -4.6% | -2.1% | -65.4% | -72.2% | -70.2% |
| EBITDA CAGR (3Y) | +31.6% | +12.4% | +0.4% | -7.8% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | -771.7% | -706.8% | -68.4% | -148.6% | -306.0% | -168.0% | -95.5% |
| Return on capital employed | -5.5% | -6.3% | -2.4% | -4.1% | -8.0% | -6.7% | -6.3% |
| Return on net worth | -5.6% | -6.3% | -2.4% | -4.2% | -8.3% | -5.7% | -3.5% |
| Debt / equity | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Long-term debt / equity | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest cover | -0.38 | -0.26 | -0.64 | -1.17 | -1.56 | -2.61 | -1.37 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.06 | 0.07 | 0.14 | 0.16 | 0.16 | 0.19 | 0.25 |
| Inventory turnover | 41.82 | 14.02 | 32.93 | 1,354.00 | 148.00 | 192.57 | 0.00 |
| Debtors turnover | 4.99 | 5.06 | 11.13 | 12.83 | 7.74 | 6.69 | 5.87 |
| EPS (₹) | (2.08) | (2.16) | (0.37) | (0.92) | (2.49) | (1.78) | (1.08) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 51.11 | 36.66 | 38.77 | 39.14 | 32.74 | 28.66 | 30.46 |
Want more history and ratios?
You're viewing the latest exchange-filed financials for Suven Life Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Board of Directors of Suven Life Sciences Limited
Suven Life Sciences has 6 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Santanu Mukherjee Also directs: Aurobindo Pharma Ltd, Sumedha Fiscal Services Ltd, Rainbow Children's Medicare Limited and 4 more | Director | 15 May 2018 | 8 Years 5 Months | Current |
| Sudharani Jasti | Whole-Time Director | 04 Jan 2013 | 13 Years 9 Months | Current |
| Venkateswarlu Jasti Also directs: Svsmk Property LLP, Jasti Property and Equity Holdings Private Limited, SVJ Property Holdings LLP and 5 more | Managing Director | 04 Jan 2010 | 16 Years 9 Months | Current |
| Vajja Sambasiva Rao | Director | 30 Jan 2024 | 2 Years 8 Months | Current |
| Seyed Ehtesham Hasnain | Director | 30 Apr 2010 | 16 Years 5 Months | Current |
| Ananthasai Padmaja Jasthi | Director | 14 Nov 2018 | 7 Years 11 Months | Current |
Peer Comparison of Suven Life Sciences Limited
Suven Life Sciences Limited is compared with the companies closest to it by revenue in the Pharma industry (Contract Research). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vivancemed India Private Limited | ₹18.19 Cr (FY 2024) | •••• | •••• | 20.0% | •••• | Bangalore, Karnataka, India |
| Pharmazz India Private Limited | ₹18.18 Cr (FY 2024) | •••• | •••• | 138.0% | •••• | New Delhi, Delhi, India |
| Monolom India Pharma Private Limited | ₹18.17 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Pune, Maharashtra, India |
| Finoso Pharma Private Limited | ₹17.69 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Hyderabad, Telangana, India |
| Semler Research Center Private Limited | ₹17.66 Cr (FY 2025) | •••• | •••• | 926.0% | •••• | Bengaluru, Karnataka, India |
| Sravathi Advance Process Technologies Private Limited | ₹17.29 Cr (FY 2025) | •••• | •••• | 40.0% | •••• | Bangalore, Karnataka, India |
| HLL Biotech Limited | ₹17.08 Cr (FY 2024) | •••• | •••• | -68.0% | •••• | Thiruvananthapuram, Kerala, India |
| Clinsync Clinical Research Private Limited | ₹15.75 Cr (FY 2025) | •••• | •••• | -38.0% | •••• | Hyderabad, Telangana, India |
| Av Processors Private Limited | ₹15.65 Cr (FY 2025) | •••• | •••• | 27.0% | •••• | Mumbai, Maharashtra, India |
| Eurofins Advinus Discovery Services Private Limited | ₹15.34 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | Bengaluru, Karnataka, India |
| Suven Life Sciences Limited this company | ₹7.11 Cr (FY 2026) | •••• | •••• | 6.8% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Suven Life Sciences by revenue in the Pharma industry (Contract Research), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Suven Life Sciences Limited
Suven Life Sciences Limited is audited by Karvy & Co for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Karvy & Co | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Shareholding Pattern of Suven Life Sciences Limited
Shareholding for the quarter ended Sep 2026: promoters hold 70.10%, foreign institutional investors hold 0.60%, domestic institutional investors hold 2.90% and retail and other public shareholders hold 26.40%.
Sep 2026
QUARTER
70.10% Promoters
2.90% DII (Domestic Institutional)
0.60% FII (Foreign Institutional)
26.40% Retail & Others
Promoter holding - history
Now 70.10% · Sep 2026High 70.20% · Jun 2026Low 67.40% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 70.10% | 70.20% | 67.40% | 67.40% |
| Public | 29.90% | 29.80% | 32.60% | 32.60% |
Charges & Borrowings of Suven Life Sciences Limited
Open charges
None
Satisfied charges
₹239.04 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Dec 2012 | Bank of Bahrain and Kuwait Bsc | ₹6 Cr | Satisfied |
| 24 Aug 2012 | Bank of Bahrain and Kuwait Bsc | ₹30 Cr | Satisfied |
| 17 Feb 2011 | Bank of India | ₹22.63 Cr | Satisfied |
| 14 Jul 2010 | State of Bank Patiala | ₹20 Cr | Satisfied |
| 30 Aug 2007 | State Bank of India | ₹25.35 Cr | Satisfied |
Total charge records: 14 View all charges
Deals & Funding of Suven Life Sciences Limited
Suven Life Sciences Limited has 19 deals on record (15 market trades, 2 funding rounds, 1 qip), with disclosed funding of ₹295.28 Cr; the latest was in January 2024.
Total deals
19
Market trades
15
Funding rounds
2
QIP
1
Rights issue
1
Disclosed funding
₹295.28 Cr
Deals on record (5 of 19)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2024 | Market trade | ₹17.4 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Sep 2023 | Market trade | ₹12 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Mar 2022 | Funding round | ₹147.64 Cr | Investors: Jasti Property and Equity Holdings Private Limited |
| Apr 2021 | Market trade | ₹7.05 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Apr 2021 | Funding round | ₹147.64 Cr | Investors: Jasti Property and Equity Holdings Private Limited |
Premium access
Full deal history
All 19 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Suven Life Sciences Limited
Suven Life Sciences Limited has 13 court cases on record: 7 filed by Suven Life Sciences, 4 filed against it, 2 where it is another party. 1 case is pending and 12 are disposed. Status as checked between 28 Sep 2026 and 03 Oct 2026.
Total cases
13
Filed by the company
7
Filed against the company
4
Pending
1
Disposed
12
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 9 | 3 | 1 |
| District courts | 4 | 1 | 0 |
Cases on record (5 of 13)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court for State of Telangana | Petition | Filed against the company by Encube Ethicals Private Limited | Disposed |
| High Court for State of Telangana | Court case (ITTA) | Filed against the company by Principal Comissioner of Income Tax-2 | Pending |
| District court, Coimbatore, Tamil Nadu | Petition | Company is another party | Disposed |
| High Court for State of Telangana | Writ petition | Filed by the company against State of Telangana | Disposed |
| High Court for State of Telangana | Writ petition | Filed by the company against Telangana State Electricity Regulatory Commission | Disposed |
Premium access
Full case history
All 13 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Suven Life Sciences Limited
Suven Life Sciences Limited has 7 MSME Form 1 returns on record between 2019 and 2021, listing 354 overdue payments to 38 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 38)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Chempure | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Varalakshmi Enterprises., | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Premium access
Full MSME payment history
Every supplier, amount and due date from all 7 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Suven Life Sciences Limited
Suven Life Sciences Limited has a workforce of 137 employees as of Apr 06, 2024.
Employee count
137
Active EPFO establishments
3
Employee growth
7.03%
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Suven Life Sciences Limited
Suven Life Sciences Limited has 22 board changes on record since 2008: 6 appointments and 16 cessations. The latest: Venkateswarlu Jasti ceased to be Managing Director on 05 May 2024.
AGM
Suven Life Sciences Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records.
Filing
Suven Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Ceased
Venkateswarlu Jasti ceased to be Managing Director.
Ceased
Vajja Sambasiva Rao ceased to be Additional Director.
Appointed
Vajja Sambasiva Rao was appointed as Director.
Ceased
Kukudala Ravi ceased to be Deputy Nodal Officer.
Charges
A charge registered on 06 Dec 2012 via Charge ID 10393384 with Bank Of Bahrain And Kuwait Bsc was fully satisfied on 07 Jan 2021.
Charges
A charge registered on 26 Feb 1990 via Charge ID 90135165 with State Bank Of India was fully satisfied on 03 Dec 2020.
Ceased
Hanumantha Rao Kokkonda ceased to be Company Secretary.
Ceased
Subba Rao Parupally ceased to be Cfo(Kmp).
Ceased
Ananthasai Padmaja Jasthi ceased to be Additional Director.
Ceased
Govinda Prasad Dasu ceased to be Director.
51 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Suven Life Sciences Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Suven Life Sciences Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Suven Life Sciences Limited
Suven Life Sciences has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AADCS4044C1ZQ | Telangana | Active | 01 Jul 2017 |
| 37AADCS4044C1ZO | Andhra Pradesh | Active | 01 Jul 2017 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Suven Life Sciences Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Suven Life Sciences Limited
Frequently Asked Questions about Suven Life Sciences Limited
Suven Life Sciences is an active public limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 09 March 1989 (37+ years old) and is registered under CIN L24110TG1989PLC009713. Listed on BSE: 530239 and NSE: SUVEN.
Suven Life Sciences reported revenue of ₹7.11 Cr for FY 2025-26 (up 6.8% YoY) based on consolidated financials.
Suven Life Sciences has 6 current directors:
- Venkateswarlu Jasti - Managing Director
- Sudharani Jasti - Whole-Time Director
- Santanu Mukherjee - Director
- Vajja Sambasiva Rao - Director
- Seyed Ehtesham Hasnain - Director
- Ananthasai Padmaja Jasthi - Director
The GSTIN of Suven Life Sciences is 36AADCS4044C1ZQ, registered in Telangana. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 37AADCS4044C1ZO (Andhra Pradesh).
The CIN (Corporate Identification Number) of Suven Life Sciences is L24110TG1989PLC009713. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Suven Life Sciences is listed on both BSE (code: 530239) and NSE (symbol: SUVEN).
Suven Life Sciences has 13 court cases on record: 7 filed by the company and 4 filed against it. 1 is pending. Most are in the high courts.
Suven Life Sciences was incorporated on 09 March 1989, making it 37+ years old. It is registered with the Registrar of Companies, Hyderabad.
Suven Life Sciences has 19 deals on record (15 market trades, 2 funding rounds, 1 qip), with disclosed funding of ₹295.28 Cr; the latest was in January 2024.
The peers of Suven Life Sciences by revenue are Vivancemed India Private Limited, Pharmazz India Private Limited, Monolom India Pharma Private Limited, Finoso Pharma Private Limited, Semler Research Center Private Limited and 5 more, all in the Pharma industry (Contract Research).
Venkateswarlu Jasti ceased to be Managing Director on 05 May 2024. Vajja Sambasiva Rao ceased to be Additional Director on 04 Mar 2024. Vajja Sambasiva Rao was appointed as Director on 30 Jan 2024. Suven Life Sciences has 22 board changes on record in total.
Suven Life Sciences has 7 MSME Form 1 returns on record between 2019 and 2021, listing 354 overdue payments to 38 micro and small suppliers. The latest return was filed on 23 Nov 2021.